72 related articles for article (PubMed ID: 10647611)
1. Tumor-targeted radionuclide therapy: trial design driven by patient dosimetry.
DeNardo SJ
J Nucl Med; 2000 Jan; 41(1):104-6. PubMed ID: 10647611
[No Abstract] [Full Text] [Related]
2. Overview of dosimetry for Systemic Targeted Radionuclide Therapy (STaRT).
Wessels BW; Syh JH; Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S39-45. PubMed ID: 16979438
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
Sharkey RM; Hajjar G; Yeldell D; Brenner A; Burton J; Rubin A; Goldenberg DM
J Nucl Med; 2005 Apr; 46(4):620-33. PubMed ID: 15809485
[TBL] [Abstract][Full Text] [Related]
4. Pretargeted anti-carcinoembryonic-antigen radioimmunotherapy for medullary thyroid carcinoma.
Machens A; Dralle H
J Clin Oncol; 2006 Jul; 24(20):e37; author reply e38. PubMed ID: 16829644
[No Abstract] [Full Text] [Related]
5. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
[TBL] [Abstract][Full Text] [Related]
6. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
7. Targeting the bone marrow: applications in stem cell transplantation.
Orchard K; Cooper M
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):267-78. PubMed ID: 15640790
[TBL] [Abstract][Full Text] [Related]
8. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
9. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry.
O'Donoghue JA; Sgouros G; Divgi CR; Humm JL
J Nucl Med; 2000 Mar; 41(3):538-47. PubMed ID: 10716330
[TBL] [Abstract][Full Text] [Related]
10. The role of radiation therapy in the management of thyroid cancer.
Strasser JF; Raben A; Koprowski C
Surg Oncol Clin N Am; 2008 Jan; 17(1):219-32, x. PubMed ID: 18177808
[TBL] [Abstract][Full Text] [Related]
11. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
Wong JY; Shibata S; Williams LE; Kwok CS; Liu A; Chu DZ; Yamauchi DM; Wilczynski S; Ikle DN; Wu AM; Yazaki PJ; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5842-52. PubMed ID: 14676105
[TBL] [Abstract][Full Text] [Related]
12. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
[TBL] [Abstract][Full Text] [Related]
14. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
Shen S; Forero A; LoBuglio AF; Breitz H; Khazaeli MB; Fisher DR; Wang W; Meredith RF
J Nucl Med; 2005 Apr; 46(4):642-51. PubMed ID: 15809487
[TBL] [Abstract][Full Text] [Related]
15. Principles of radioimmunotherapy for hematologists and oncologists.
Press OW; Rasey J
Semin Oncol; 2000 Dec; 27(6 Suppl 12):62-73. PubMed ID: 11226002
[TBL] [Abstract][Full Text] [Related]
16. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Brans B; Bodei L; Giammarile F; Linden O; Luster M; Oyen WJG; Tennvall J
Eur J Nucl Med Mol Imaging; 2007 May; 34(5):772-786. PubMed ID: 17268773
[TBL] [Abstract][Full Text] [Related]
17. Systemic targeted radionuclide therapy: potential new areas.
Wong JY
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S74-82. PubMed ID: 16979445
[TBL] [Abstract][Full Text] [Related]
18. [Cytomorphological characteristics of radiation-induced changes in thyroid gland tumor].
Nikitina NI; Kiseleva ES
Vestn Akad Med Nauk SSSR; 1976; (6):39-43. PubMed ID: 997850
[No Abstract] [Full Text] [Related]
19. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".
Flux G; Bardies M; Chiesa C; Monsieurs M; Savolainen S; Strand SE; Lassmann M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1699-700. PubMed ID: 17565497
[No Abstract] [Full Text] [Related]
20. External beam radiation therapy for thyroid cancer.
Brierley JD; Tsang RW
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):497-509, xi. PubMed ID: 18502339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]